ARTICLE TYPE

Enantioselective formal synthesis of *ent*-rhynchophylline and *ent*-isorhynchophylline

Mercedes Amat,*[a] Carlos Ramos,[a] Maria Pérez,[a] Elies Molins,[b] Pedro Florindo,[a,c] Maria M. M. Santos[c] and Joan Bosch[a]

Starting from (S)-tryptophanol, a formal synthesis of *ent*-rhynchophylline and *ent*-isorhynchophylline, involving stereoselective cyclocondensation, spirocyclization, and
10 **alkylation reactions, and the final adjustment of the oxidation level at the oxindole and piperidine moieties, is reported.**

Oxindole alkaloids are a diverse group of natural products[1] characterized by the presence of a spiro[pyrrolidine-3,3'-oxindole] ring system,[2] a privileged heterocyclic motif associated
15 with a variety of bioactivity profiles.[3] Most of the oxindole alkaloids incorporate an unrearranged secologanin skeleton and are biogenetically formed by oxidative rearrangement of secoyohimbane- or heteroyohimbane-type indole alkaloids. Representative members of this group are rhynchophylline and
20 isorhynchophylline (Fig.1),[4] a pair of C-7 epimers that can be equilibrated through a ring-opened form via retro-Mannich/Mannich reactions. These alkaloids exhibit a number of pharmacological effects[5] and are the major tetracyclic oxindole components of *Uncaria* species, which have long been used in
25 traditional Oriental medicine.[6]

Fig. 1

Although the stereogenic quaternary spirocenter and the three stereogenic centers on the piperidine ring make rhynchophyllines
30 attractively challenging synthetic targets, they have received limited attention from the synthetic standpoint.[7] In fact, only two different strategies have been used to assemble the spiro[pyrrolidine-3,3'-oxindole] moiety of these alkaloids: either a biomimetic oxidative rearrangement from a indolo[2,3-
35 a]quinolizidine derivative[4g,7c,d] or a condensation of 2-hydroxytryptamine with an appropriate aldehyde.[7a,b]

We present here an enantioselective synthesis of *ent*-rhynchophylline and *ent*-isorhynchophylline using (S)-tryptophanol as the starting material, which not only incorporates
40 the tryptamine moiety of the natural products but also acts as the source of chirality. Our approach takes advantage of the methodology we have reported for the enantioselective spirocyclization of tryptophanol-derived oxazolopiperidone lactams, involving a Lewis acid-promoted cyclization of the
45 corresponding N_{ind}-tosyl derivatives in the presence of Et$_3$SiH.[8] Scheme 1 outlines the initial steps of the synthesis and the overall synthetic strategy.

The required bicyclic lactam **2**, which already incorporates an acetate chain at the 4-position of the piperidone ring, was
50 prepared[9] by cyclocondensation of (S)-tryptophanol with the prochiral aldehyde-diester **1**, in a process that involves the enantioselective desymmetrization[10] of two enantiotopic chains.[11] The *N*-indole deactivating group, needed to direct the key cyclization on the indole 3-position, was benzenesulfonyl,[12]
55 which was introduced in excellent yield under conventional solid-liquid phase transfer conditions. Treatment of sulfonyl derivative **3** with TiCl$_4$ in the presence of Et$_3$SiH resulted in a regio- and stereocontrolled cyclization, with concomitant reduction of the initially formed spiroindoleninium intermediate, leading to the
60 tetracyclic spiroindoline **4** as a single stereoisomer in 93% yield. Interestingly, **4** already embodies three of the four stereogenic centers of the target natural products, with the appropriate relative configuration.


65 **Scheme 1** Initial steps of the synthesis and synthetic strategy. *Reagents*

As outlined in Scheme 1, the synthesis of rhynchophyllines from the spiroindoline **4** would involve the following transformations: i) removal of the hydroxymethyl group, ii) stereoselective introduction of the C-20 ethyl substituent to obtain the required *trans* C_{15}-C_{20} stereochemistry, iii) oxidation of the indoline moiety to the oxindole functionality, iv) chemoselective reduction of the lactam carbonyl, and finally, v) introduction of the C-16 methoxyvinyl appendage.

The removal of the hydroxymethyl substituent, which has acted as an element of stereocontrol during the spirocyclization step, was accomplished by oxidation to a carboxylic acid, followed by a radical reductive decarbonylation via a selenoester[13] to give the tetracyclic lactam **5** (Scheme 2).

Scheme 2 Formal enantioselective synthesis of *ent*-rhynchophylline and *ent*-isorhynchophylline. *Reagents and conditions:* (a) IBX, DMSO, rt, 20 h, 79%; (b) NaClO₂, NaH₂PO₄, CH₃CN, *t*-BuOH, H₂O, 1-methylcyclohexene, rt, 1 h, then (PhSe)₂, *n*-PBu₃, CH₂Cl₂, reflux, 16 h, 64%; (c) AIBN, *n*-Bu₃SnH, benzene, reflux, 1 h, 65%; (d) LiBH₄, Et₂O, reflux, 48 h, 83%; (e) NaH, THF, rt, 2 h, then MPMCl, Bu₄NI, reflux, 16 h, 87%; (f) KHMDS, THF, rt, 2 h, then EtI, HMPA, rt, 16 h, 72% (20-*epi*-**7**, 19%); (g) DDQ, CH₂Cl₂/H₂O, rt, 1 h, 93%; (h) IBX, DMSO, rt, 20 h; (i) NaClO₂, NaH₂PO₄, CH₃CN, *t*-BuOH, H₂O, 1-Me-1-Chx, rt, 1.5 h, then Me₃SiCl, MeOH, rt, 24 h, 66% (three steps); (j) Na/Hg 5%, NaH₂PO₄, MeOH, 0 ºC, 15 min, 88%; (k) PhIO, CH₂Cl₂, rt, 48 h, 70%; (l) AlH₃, THF, −78 ºC (addition) to −50 ºC, 30 min, then MeOH, rt, 20 min, then NaBH₃CN, AcOH, rt, 20 min, 47%.

At this point, to complete the carbon skeleton of **11**, a known[7b] synthetic precursor of rhynchophyllines, only the introduction of the C-20 ethyl substituent remained to be done. However, to avoid the competitive alkylation at the α-position of the ester group, the alkylation was performed from the protected alcohol derivative **6**, which was obtained in good yield by LiBH₄ reduction of **5** followed by protection with *p*-methoxybenzyl chloride. The alkylation of **6** was performed with ethyl iodide, using KHMDS as the base and HMPA as the cosolvent, to stereoselectively give the expected *trans*-3,4-disubstituted 2-piperidone derivative **7**.[14] Then, the C-15 acetate chain was reinstalled (compound **8**) by oxidative removal of the *p*-methoxybenzyl protecting group of **7** with DDQ, followed by oxidation of the resulting alcohol to a carboxylic acid and a subsequent esterification. After a smooth and efficient deprotection of the indoline nitrogen with 5% Na/Hg, spiroindoline **9** was oxidized with PhIO, leading to oxindole **10** in 70% yield. Finally, chemoselective reduction of the six-membered lactam carbonyl, without affecting the oxindole moiety, was satisfactorily accomplished by sequential treatment of **10** with AlH₃ and NaBH₃CN.[15] The resulting oxindole **11** showed ¹H- and ¹³C-NMR spectral data coincident with those reported[7c] for *rac*-**11**. Taking into account that *rac*-**11** has previously been converted[7b] to (±)-rhynchophylline and (±)-isorhynchophylline, the synthesis of oxindole **11** constitutes a formal enantioselective synthesis of the non-natural enantiomers of these alkaloids.

The results reported herein further illustrate the potential of tryptophanol-derived oxazolopiperidone lactams for the enantioselective synthesis of indole alkaloids.[16] Two notable aspects of the synthesis are the efficient, highly convergent, and totally stereoselective assembling of the tetracyclic spiro[indoline-3,1'-indolizidine] ring system of rhynchophyllines and the generation of the required oxindole functionality by oxidation of an *N*-unsubstituted indoline.[17]

Notes and references

ᵃ Laboratory of Organic Chemistry, Faculty of Pharmacy, and Institute of Biomedicine (IBUB), University of Barcelona, 08028-Barcelona, Spain. E-mail: amat@ub.edu; Fax: +34 93 402 45 39; Tel: +34 93 402 45 40
ᵇ Institut de Ciència de Materials (CSIC), Campus UAB, 08193-Cerdanyola, Spain
ᶜ Faculty of Pharmacy, Research Institute for Medicines and Pharmaceutical Sciences, University of Lisbon, 1649-003 Lisbon, Portugal.

1   For reviews, see: (a) J. E. Saxton, in *The Alkaloids*, ed. R. H. F. Manske, Academic Press, New York, 1965, vol. 8, pp. 59–91; (b) J. S. Bindra, in *The Alkaloids*, ed. R. H. F. Manske, Academic Press, New York, 1973, vol. 14, pp. 84–121; (c) R. T. Brown, *Indoles, The Monoterpenoid Indole Alkaloids*, in *The Chemistry of Heterocyclic*

Compounds, ed. J. E. Saxton, A. Weissberger, E. C. Taylor, Wiley, New York, 1983, vol. 25, Part 4, pp. 85–97.

2 For reviews on the synthesis of oxindole alkaloids, see: (a) C. Marti, E. M. Carreira, *Eur. J. Org. Chem.*, **2003**, 2209. (b) B. M. Trost, M. K. Brennan, *Synthesis*, **2009**, 3003; (c) F. Zhou, Y.-L. Liu, J. Zhou, *Adv. Synth. Catal.*, **2010**, *325*, 1381.

3 C.V. Galliford, K. A. Scheidt, *Angew. Chem. Int. Ed.*, **2007**, *46*, 8748.

4 Isolation: (a) H. Kondo, T. Fukuda, M. Tomita, *J. Pharm. Soc. Japan*, **1928**, *48*, 321; (b) H. Kondo, T. Ikeda, *J. Pharm. Soc. Japan*, **1937**, *57*, 881; Structural elucidation: (c) J. C. Seaton, L. Marion, *Can. J. Chem.*, **1957**, *35*, 1102; (d) J. C. Seaton, R. Tondeur, L. Marion, *Can. J. Chem.*, **1958**, *36*, 1031; (e) J. C. Seaton, M. D. Nair, O. E. Edwards, L. Marion, *Can. J. Chem.*, **1960**, *38*, 1035; Stereochemistry: (f) Y. Ban, T. Oishi, *Tetrahedron Lett.*, **1961**, 791; (g) N. Finch, W. I. Taylor, *J. Am. Chem. Soc.*, **1962**, *84*, 3871; (h) Y. Ban, T. Oishi, *Chem. Pharm. Bull.*, **1963**, *11*, 451; (i) W. F. Trager, C. M. Lee, J. D. Phillipson, R. E. Haddock, D. Dwuma-Badu, A. H. Beckett, *Tetrahedron*, **1968**, *24*, 523; X-Ray crystal structure (j) G. Laus, K. Wurst, *Helv. Chim. Acta*, **2003**, *86*, 181.

5 (a) T.-H. Kang, Y. Murakami, K. Matsumoto, H. Takayama, M. Kitajima, N. Aimi, H. Watanabe, *Eur. J. Pharmacol.*, **2002**, *455*, 27; (b) T.-H. Kang, Y. Murakami, H. Takayama, M. Kitajima, N. Aimi, H. Watanabe, K. Matsumoto, *Life Sci.*, **2004**, *76*, 331; (c) C.-H. Chou, C.-L. Gong, C.-C. Chao, C.-H. Lin, C.-Y. Kwan, C.-L. Hsieh, Y.-M. Leung, *J. Nat. Prod.*, **2009**, *72*, 830; For reviews, see: (d) J-S. Shi, J.-X. Yu, X.-P. Chen, R.-X. Xu, *Acta Pharmacol. Sin.*, **2003**, *24*, 97; (e) J. Zhou, S. Zhou, *J. Ethnopharmacol.*, **2010**, *132*, 15.

6 W. Tang, G. Eisenbrand, in *Handbook of Chinese Medicinal Plants*, Wiley, 2011, vol. 2, pp. 1213–1221.

7 (a) Partial synthesis: from dihydrocorynantheine, see ref 4g; from secologanin, see R. R. Brown, C. L. Chapple, R. Platt, *Tetrahedron Lett.*, **1976**, 1401; (b) Total racemic synthesis: Y. Ban, M. Seto, T. Oishi, *Chem. Pharm. Bull.*, **1975**, *23*, 2605; (c) Formal racemic synthesis: A. Deiters, M. Pettersson, S. F. Martin *J. Org. Chem.*, **2006**, *71*, 6547; (d) Enantioselective formal synthesis: K. Nagata, H. Ishikawa, A. Tanaka, M. Miyazaki, T. Kanemitsu, T. Itoh, *Heterocycles*, **2010**, *81*, 1791.

8 M. Amat, M. M. M. Santos, A. M. Gómez, D. Jokic, E. Molins, J. Bosch, *Org. Lett.*, **2007**, *9*, 2907.

9 Minor amounts (~10%) of the 7,8a-*epi* derivative were also formed (**2**:7,8a-*epi*-**2** ratio, 87:13).

10 For related desymmetrizations, see: (a) M. Amat, O. Bassas, N. Llor, M. Cantó, M. Pérez, E. Molins, J. Bosch, *Chem.-Eur. J.*, **2006**, *12*, 7872; (b) M. Amat, M. M. M. Santos, O. Bassas, N. Llor, C. Escolano, A. Gómez-Esqué, E. Molins, S. M. Allin, V. McKee, J. Bosch, *J. Org. Chem.*, **2007**, *72*, 5193. For reviews on the desymmetrization of prochiral or *meso* substrates, see: (c) R. S. Ward, *Chem. Soc. Rev.*, **1990**, *19*, 1; (d) B. Danieli, G. Lesma, D. Passarella, S. Riva, in *Advances in the Use of Synthons in Organic Chemistry*, ed. A. Dondoni, JAI Press, London, 1993, vol. 1, pp. 143–219; (e) E. Schoffers, A. Golebiowski, C. R. Johnson, *Tetrahedron*, **1996**, *52*, 3769; (f) M. C. Willis, *J. Chem. Soc., Perkin Trans. 1*, **1999**, 1765; (g) B. Danieli, G. Lesma, D. Passarella, A. Silvani, *Curr. Org. Chem.*, **2000**, *4*, 231.

11 The absolute configuration of **2** and **5** was unambiguously established by X-ray crystallographic analysis. For full crystal details, see the electronic supplementary information.

12 Our initial studies were carried out starting from a lactam bearing a tosyl substituent on the indole nitrogen. However, all attempts to introduce the ethyl substituent at the α-position of the lactam carbonyl from the N_{ind}-tosyl analog of **6** were unsuccessful. In some cases the alkylation occurred on the methyl group of the tosyl substituent.

13 S. M. Allin, C. I. Thomas, J. E. Allard, K. Doyle, M. R. J. Elsegood, *Tetrahedron Lett.*, **2004**, *45*, 7103.

14 Minor amounts of 20-*epi*-**7** were also formed (**7**:20-*epi*-**7** ratio, 4:1). Performing the alkylation at a lower temperature resulted in a lower yield.

15 S. F. Martin, M. Mortimore, *Tetrahedron Lett.*, **1990**, *31*, 4557.

16 For reviews, see: (a) M. Amat, M. Pérez, J. Bosch, *Synlett*, **2011**, 143; (b) M. M. M. Santos in *Heterocyclic Targets in Advanced Organic Synthesis*, ed. M. do C. Carreiras, J. Marco-Contelles, Research Signpost, Kerala, India, 2011, pp. 69−82. See also: (c) S. M. Allin, C. I. Thomas, K. Doyle, M. R. J. Elsegood, *J. Org. Chem.*, **2005**, *70*, 357; (d) S. M. Allin, J. S. Khera, J. Witherington, M. R. J. Elsegood, *Tetrahedron Lett.*, **2006**, *47*, 5737; (e) M. Amat, A. Gómez-Esqué, C. Escolano, M. M. M. Santos, E. Molins, J. Bosch, *J. Org. Chem.*, **2009**, *74*, 1205.

17 An enantioselective formal synthesis of rhynchophyllines involving an organocatalyzed asymmetric Michael addition reaction to generate the first stereocenter has recently been reported: H. Zhang, X. Ma, H. Kang, L. Hong, R. Wang, *Chem. Asian. J.* doi:10.1002/asia.201201046.